2021
Seeking progress in disease modification in Parkinson disease
Lungu C, Cedarbaum J, Dawson T, Dorsey E, Faraco C, Federoff H, Fiske B, Fox R, Goldfine A, Kieburtz K, Macklin E, Matthews H, Rafaloff G, Saunders-Pullman R, Schor N, Schwarzschild M, Sieber B, Simuni T, Surmeier D, Tamiz A, Werner M, Wright C, Wyse R. Seeking progress in disease modification in Parkinson disease. Parkinsonism & Related Disorders 2021, 90: 134-141. PMID: 34561166, DOI: 10.1016/j.parkreldis.2021.09.006.Peer-Reviewed Original ResearchConceptsDisease modificationParkinson's diseaseDisease-modifying benefitsNovel trial designsDrug therapyPatient populationTrial failuresTherapeutic targetTrial designNeurological disordersRelevant biomarkersTherapeutic developmentNational InstituteDiseaseReview articleResearch prioritiesKey stakeholder groupsFailureLikelihood of successTherapyStrokeBiomarkers
2011
Revision of the criteria for Alzheimer's disease: A symposium
DeKosky ST, Carrillo MC, Phelps C, Knopman D, Petersen RC, Frank R, Schenk D, Masterman D, Siemers ER, Cedarbaum JM, Gold M, Miller DS, Morimoto BH, Khachaturian AS, Mohs RC. Revision of the criteria for Alzheimer's disease: A symposium. Alzheimer's & Dementia 2011, 7: e1-e12. PMID: 21322828, DOI: 10.1016/j.jalz.2010.12.007.Peer-Reviewed Original ResearchConceptsAlzheimer's diseaseClinical diagnosisRelated Disorders Association criteriaAlzheimer's Association Research RoundtableDefinitive clinical diagnosisCurrent diagnostic criteriaPotential diagnostic biomarkersPresymptomatic Alzheimer's diseaseCurrent standardMild cognitive impairmentClinical presentationAD pathologyClinicopathologic correlationAssociation criteriaDiagnostic criteriaMild stageCognitive impairmentDiagnostic biomarkersCommunicative DisordersResearch RoundtableDiseaseBetter ascertainmentGenetics of ADCurrent criteriaDiagnosis